Safety and Efficacy of Otaplimastat in Patients with Acute Ischemic Stroke Requiring tPA (SAFE-TPA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jong S. | - |
dc.contributor.author | Lee, Kyung Bok | - |
dc.contributor.author | Park, Jong-Ho | - |
dc.contributor.author | Sung, Sang Min | - |
dc.contributor.author | Oh, Kyungmi | - |
dc.contributor.author | Kim, Eung-Gyu | - |
dc.contributor.author | Chang, Dae-il | - |
dc.contributor.author | Hwang, Yang Ha | - |
dc.contributor.author | Lee, Eun-Jae | - |
dc.contributor.author | Kim, Won-Ki | - |
dc.contributor.author | Ju, Chung | - |
dc.contributor.author | Kim, Byung Su | - |
dc.contributor.author | Ryu, Jei-Man | - |
dc.date.accessioned | 2021-08-11T08:37:57Z | - |
dc.date.available | 2021-08-11T08:37:57Z | - |
dc.date.issued | 2020-02 | - |
dc.identifier.issn | 0364-5134 | - |
dc.identifier.issn | 1531-8249 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/3157 | - |
dc.description.abstract | Objective Otaplimastat is a neuroprotectant that inhibits matrix metalloprotease pathway, and reduces edema and intracerebral hemorrhage induced by recombinant tissue plasminogen activator (rtPA) in animal stroke models. We aimed to assess the safety and efficacy of otaplimastat in patients receiving rtPA. Methods This was a phase 2, 2-part, multicenter trial in stroke patients (19-80 years old) receiving rtPA. Intravenous otaplimastat was administered <30 minutes after rtPA. Stage 1 was a single-arm, open-label safety study in 11 patients. Otaplimastat 80 mg was administered twice daily for 3 days. Stage 2 was a randomized, double-blind, placebo-controlled study involving 69 patients, assigned (1:1:1) to otaplimastat 40 mg, otaplimastat 80 mg, or a placebo. The primary endpoint was the occurrence of parenchymal hematoma (PH) on day 1. Secondary endpoints included serious adverse events (SAEs), mortality, and modified Rankin scale (mRS) distribution at 90 days ( identifier: NCT02787278). Results No safety issues were encountered in stage 1. The incidence of PH during stage 2 was comparable: 0 of 22 with the placebo, 0 of 22 with otaplimastat 40 mg, and 1 of 21 with the 80 mg dose. No differences in SAEs (13%, 17%, 14%) or death (8.3%, 4.2%, 4.8%) were observed among the 3 groups. Three adverse events (chills, muscle rigidity, hepatotoxicity) were judged to be related to otaplimastat. Interpretation Intravenous otaplimastat adjunctive therapy in patients receiving rtPA is feasible and generally safe. The functional efficacy of otaplimastat needs to be investigated with further large trials. ANN NEUROL 2019 | - |
dc.format.extent | 13 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | John Wiley & Sons Inc. | - |
dc.title | Safety and Efficacy of Otaplimastat in Patients with Acute Ischemic Stroke Requiring tPA (SAFE-TPA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1002/ana.25644 | - |
dc.identifier.scopusid | 2-s2.0-85075742713 | - |
dc.identifier.wosid | 000501022500001 | - |
dc.identifier.bibliographicCitation | Annals of Neurology, v.87, no.2, pp 233 - 245 | - |
dc.citation.title | Annals of Neurology | - |
dc.citation.volume | 87 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 233 | - |
dc.citation.endPage | 245 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.subject.keywordPlus | TISSUE-PLASMINOGEN ACTIVATOR | - |
dc.subject.keywordPlus | HEMORRHAGIC TRANSFORMATION | - |
dc.subject.keywordPlus | MATRIX METALLOPROTEINASES | - |
dc.subject.keywordPlus | THROMBOLYTIC THERAPY | - |
dc.subject.keywordPlus | ALTEPLASE | - |
dc.subject.keywordPlus | THROMBECTOMY | - |
dc.subject.keywordPlus | INJURY | - |
dc.subject.keywordPlus | BRAIN | - |
dc.subject.keywordAuthor | Stroke | - |
dc.subject.keywordAuthor | Neurology | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.